The Federal Circuit affirmed an ITC exclusion order against FS.com’s imported fiber optic equipment, holding that Corning’s high-density fiber optic patents were enabled and that the asserted claims were infringed.
The Federal Circuit affirmed that patents claiming a method for distributing digital promotional content—loading branding images when a user’s GPS location matches a specified geographic area—are directed to the abstract idea of providing information based on meeting a condition, and contain n
The Federal Circuit affirmed invalidity of UCB’s transdermal rotigotine patch patent, holding that prior art ranges overlapping with claimed ranges create a presumption of obviousness that the patentee must rebut by showing criticality or unexpected results.
The Federal Circuit affirmed that Arbutus Biopharma’s patent on stable nucleic acid-lipid particles (SNALPs) with non-lamellar morphology was inherently anticipated by an earlier Arbutus patent, holding that when the same formulation process disclosed in both patents naturally produces the cla
The Federal Circuit affirmed willful infringement of Ironburg’s video game controller patent by Valve’s Steam Controller, while vacating and clarifying the standard for IPR estoppel — holding that the patent owner, not the petitioner, bears the burden of proving estoppel applies.
The Federal Circuit revived Apple’s Administrative Procedure Act challenge to the USPTO’s Fintiv policy, under which the PTAB discretionarily denies institution of inter partes reviews when parallel district court litigation is proceeding, allowing the challenge to be heard on its merits
The Federal Circuit reversed the PTAB’s finding of no obviousness, holding that when two prior art references address the same technical problem and one provides a known technique for solving it, a skilled artisan would be motivated to combine them—the Board’s contrary conclusion contrad
The Federal Circuit affirmed the PTAB’s ruling that the University of Minnesota’s antiviral drug patent—directed to phosphoramidate prodrugs of nucleoside derivatives—lacked adequate written description support for its broad genus claims, because the patent’s specification disclose
The Federal Circuit affirmed the delisting of Jazz Pharmaceuticals’ REMS system patent from the FDA Orange Book, holding that a patent claiming a drug distribution and monitoring system — rather than the drug itself or a method of using it — is ineligible for Orange Book listing.
The Federal Circuit affirmed that Minerva Surgical’s demonstration of 15 fully functional endometrial ablation device prototypes at an industry trade show—more than a year before the patent’s priority date—triggered the public use bar of pre-AIA § 102(b) and invalidated the asserted pate